Table 1.
Examined pathologies and thresholds
| Pathology | Description |
|---|---|
| A | Amyloid-β staged by amyloid phase, A2 or A3a |
| B | Neurofibrillary tangles staged by Braak and Braak, B2 or B3a |
| C | Neuritic plaque severity by CERAD score, C2 or C3a |
| TDP | All ALS cases with TDP-43 pathology and all other cases with neocortical or hippocampal formation TDP-43 pathology |
| LB | All cases with Lewy pathology affecting the substantia nigra, the hippocampal formation and/or neocortical regions |
| CAA | Cerebral amyloid angiopathy in neocortical and amygdala, hippocampus, anterior cingulate, cerebellum, caudate, putamen or thalamus, stage 2 or 3b |
| CVD | Two or more: infarcts (large, lacunar or micro), moderate/severe neocortical CAA or moderate/severe arteriolosclerosisc |
| Tau | Any case with a primary or secondary diagnosis of corticobasal degeneration, progressive supranuclear palsy, Pick disease, globular glial tauopathy or tauopathy unclassifiable |
| GCI | Any case with a primary or secondary diagnosis of MSA |
| Rare | ALS cases with SOD1 mutations, frontotemporal lobar degeneration with fused in sarcoma (FUS)-positive inclusions, frontotemporal lobar degeneration with ubiquitin-positive inclusions, hereditary diffuse leukoenchelopathy with spheroids, adult polyglucosan body disease |